Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Heart Failure II: Pathophysiology
Regulation of Angiogenesis and Blood Supply
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin II Receptor Blockers
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 20, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
Published on: May 24, 2024
Research into endothelin, a potent vasoconstrictor, began 25 years ago. Endothelin receptor antagonism is now a key treatment for pulmonary arterial hypertension.
Area of Science:
Background:
Discussion:
Key Insights:
Outlook: